Curanex Forms World Class Scientific Advisory Board
MWN-AI** Summary
Curanex Pharmaceuticals Inc. (Nasdaq: CURX), a developmental-stage pharmaceutical company specializing in botanical drugs for inflammatory diseases, announced the formation of a new Scientific Advisory Board. This initiative, reported on March 5, 2026, aims to enhance the company's research and development efforts, including upcoming clinical trials and intellectual property expansion. The Advisory Board will also play a vital role in defining Curanex's go-to-market strategies, focusing on commercialization and creating strategic value.
The inaugural board will consist of five distinguished members, drawing from both industry and academic sectors. The two industry veterans possess extensive commercial expertise, while the three academic members are leaders in research, reflecting a combination of practical and theoretical prowess that Curanex aims to leverage. CEO Jun Liu underscored the importance of this achievement, suggesting that the ability to attract such respected figures highlights the promising potential of their research efforts to date.
Curanex's lead drug candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties and a long history of safe use in humans, particularly in treating conditions like ulcerative colitis, diabetes, and gout. The company has shown Phyto-N's effectiveness in animal models for six inflammatory diseases and is currently preparing for FDA-required preclinical studies before submitting an Investigational New Drug application, with plans to initiate Phase I clinical trials in late 2026.
With this development, Curanex reaffirms its commitment to innovative treatments for inflammatory diseases while emphasizing the strategic role that the new Scientific Advisory Board will play in accelerating its growth and fostering shareholder confidence. For further inquiries, Curanex encourages interested parties to visit their website or contact them directly.
MWN-AI** Analysis
Curanex Pharmaceuticals Inc. (Nasdaq: CURX) has recently announced the formation of a Scientific Advisory Board, which can significantly enhance its credibility and strategic direction in the competitive landscape of pharmaceutical development, particularly within its focus on botanical drugs for inflammatory diseases. The inclusion of former Fortune 100 executives and leading academic figures suggests a robust potential for successful research and commercialization of its lead candidate, Phyto-N.
Investors should view this move as a positive signal, indicating that Curanex is laying a strong foundation for its clinical development and market entry strategy. Phyto-N boasts a long history of use in China, demonstrating its safety and efficacy across several inflammatory conditions. This is particularly relevant as the company prepares for Investigational New Drug (IND) submission and Phase I clinical trials, projected for late 2026. The efficacy of Phyto-N, validated in animal models for diseases such as ulcerative colitis, positions the company favorably as it targets a significant and growing market.
However, potential investors must approach this opportunity with caution. The pharmaceutical pipeline is fraught with uncertainty, especially for developmental-stage companies. While the formation of the advisory board marks a critical achievement, the actual success of the drug will depend on the outcomes of forthcoming clinical trials and the regulatory landscape.
Given the current volatility within the biotech sector, a prudent approach would be to monitor key milestones for Curanex closely, particularly the results from preclinical studies and upcoming trial initiation. The market may respond favorably to positive news; hence, investors could consider maintaining a position while remaining vigilant about the risks inherent in pharmaceutical development. Overall, Curanex presents an exciting, albeit speculative, investment opportunity in the burgeoning field of botanical therapeutics.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Board Includes Former Fortune 100 Pharma Executive and Leading US Medical Research Academic
Jericho, New York, March 05, 2026 (GLOBE NEWSWIRE) -- Curanex Pharmaceuticals Inc. (Nasdaq: CURX) (“Curanex” or the “Company”), a development-stage pharmaceutical company focused on the discovery and development of botanical drugs for the treatment of inflammatory diseases, today announced the formation of a new Scientific Advisory Board, reporting to and supporting the executive team and Board of Directors of Curanex.
The purpose of this Scientific Advisory Board will be two-fold. First, the Advisory Board will support all research and development, including upcoming clinical trials, technical support, and intellectual property expansion and enhancement. Second, the Advisory Board will play a critical role in shaping the go-to-market strategy, commercialization and strategic value creation process.
The Scientific Advisory Board shall initially consist of a total of 5 world class members, including two from industry with deep commercial expertise in the life sciences space, and three well-regarded leading academic and research individuals.
Jun Liu, our Chief Executive Officer, commented “the formation of this Scientific Advisory Board is a critical achievement for Curanex. The ability to attract a group of highly respected leaders from both the research and commercial fields within the life sciences industry is a strong indication of the potential success of our research to date. We strongly believe our lead botanical drug candidate, Phyto-N, represents a differentiated multi-target therapeutic approach with potential applications in inflammatory diseases. We look forward to unveiling all of the initial members of our Scientific Advisory Board shortly for the benefit of all shareholders.”
About Curanex Pharmaceuticals Inc
Curanex Pharmaceuticals Inc is a developmental-stage pharmaceutical company headquartered in Jericho, New York, dedicated to discovering and developing botanical drugs for inflammatory diseases. Its lead candidate, Phyto-N, is a botanical extract from a single plant with proven anti-inflammatory properties that acts via multiple targets and mechanisms. Phyto-N has a long history of human use, having treated thousands of patients with inflammatory diseases over 30 years in China, demonstrating favorable tolerability.
The Company has validated Phyto-N's effects in animal models of six inflammatory diseases: ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout. The Company's primary development focus is moderate to severe ulcerative colitis.
Phyto-N is currently advancing through FDA-required preclinical studies in preparation for an Investigational New Drug (IND) submission, with Phase I clinical trials targeted to initiate in the fourth quarter of 2026, pending completion of required studies and regulatory clearance.
For more information, visit the Company’s website at www.curanexpharma.com.
Forward-Looking Statements
All statements other than statements of historical fact in this announcement are forward-looking statements. These forward-looking statements are made as of the date hereof and involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “potential,” “continue,” “is/are likely to” or other similar expressions. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and in its other filings with the SEC.
For more information, please contact:
Curanex Pharmaceuticals Inc
Attn: Liqin Xie, Chief Operating Officer
info@curanexpharma.com.
FAQ**
How does Curanex Pharmaceuticals Inc (CURX) plan to leverage the experience of the new Scientific Advisory Board to enhance its research and development efforts for Phyto-N's upcoming clinical trials?
Can you elaborate on the strategic initiatives Curanex Pharmaceuticals Inc (CURX) will undertake to commercialize Phyto-N and integrate feedback from the Scientific Advisory Board?
What specific metrics will Curanex Pharmaceuticals Inc (CURX) use to measure the success of the Scientific Advisory Board in supporting its goals for intellectual property and market entry strategies?
In what ways does Curanex Pharmaceuticals Inc (CURX) anticipate that the expertise from former Fortune 100 Pharma executives will influence its approach to navigating FDA-required regulatory processes for Phyto-N?
**MWN-AI FAQ is based on asking OpenAI questions about Curanex Pharmaceuticals Inc (NASDAQ: CURX).
NASDAQ: CURX
CURX Trading
12.89% G/L:
$0.4572 Last:
643,724 Volume:
$0.45 Open:
